Abiraterone Acetate
Showing 1 - 25 of 1,207
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate
Not yet recruiting
- High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
- dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- placebo; abiraterone acetate tablets; prednisone tablets
- (no location specified)
Oct 20, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Tumors Trial (MK-5684, Dexamethasone, Fludrocortisone
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
- MK-5684
- +6 more
- (no location specified)
Nov 21, 2023
Medicines Called Enzalutamide and Abiraterone in People With
Not yet recruiting
- Prostatic Neoplasms, Castration-Resistant
- Enzalutamide
- Abiraterone acetate
-
New York, New YorkPfizer Inc
Jul 21, 2023
Prostate Cancer Trial (Neoadjuvant treatment)
Not yet recruiting
- Prostate Cancer
- Neoadjuvant treatment
- (no location specified)
Oct 19, 2022
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Metastatic Castration-resistant Prostate Cancer Trial (Niraparib plus Abiraterone Acetate (Nira/AA) combination,
Available
- Metastatic Castration-resistant Prostate Cancer
- Niraparib plus Abiraterone Acetate (Nira/AA) combination
- Prednisone/Prednisolone
- (no location specified)
Aug 24, 2022
Abiraterone Acetate in Indian Metastatic, Castration Resistant
Withdrawn
- Prostate Cancer
- Abiraterone Acetate
-
Bangalore, India
- +2 more
Aug 15, 2022
High-Risk Prostate Cancer Trial in Portland (Capivasertib, abiraterone acetate)
Not yet recruiting
- High-Risk Prostate Cancer
- Capivasertib
- abiraterone acetate
-
Portland, OregonVA Portland Health Care System, Portland, OR
Jan 17, 2023
Prostate Cancer Trial in United States (Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone))
Active, not recruiting
- Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Miami, Florida
- +4 more
Dec 14, 2022
Prostate Cancer Trial in Tampa (Abiraterone Acetate)
Active, not recruiting
- Prostate Cancer
- Abiraterone Acetate
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 3, 2023
Congenital Adrenal Hyperplasia Trial in United States (Abiraterone acetate, Placebo, Hydrocortisone)
Withdrawn
- Congenital Adrenal Hyperplasia
- Abiraterone acetate
- +3 more
-
Los Angeles, California
- +3 more
Jan 30, 2023
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Abiraterone Acetate/Niraparib
- +5 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 9, 2023
Prostatic Tumors Trial in Bronx (Abiraterone Acetate, Prednisone)
Active, not recruiting
- Prostatic Neoplasms
- Abiraterone Acetate
- Prednisone
-
Bronx, New YorkMontefiore Medical Center
Sep 22, 2022
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma Trial in Houston (Abiraterone Acetate, Bicalutamide, Degarelix)
Active, not recruiting
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Abiraterone Acetate
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Metastatic Cancer, Tumor, Prostate Trial in Bronx (Abiraterone acetate, Apalutamide, Enzalutamide)
Not yet recruiting
- Metastatic Cancer
- Neoplasm, Prostate
- Abiraterone acetate
- +2 more
-
Bronx, New YorkJames J. Peters VA Medical Center
Jun 16, 2022
High-risk Prostate Cancer, Neoadjuvant Therapy Trial in Shanghai (Abiraterone acetate, Fluzoparib, Prednisone)
Recruiting
- High-risk Prostate Cancer
- Neoadjuvant Therapy
- Abiraterone acetate
- +4 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 6, 2022
Abiraterone Acetate, Gene Polymorphism, Pharmacokinetic Trial in Wuhan (Abiraterone acetate tablets)
Active, not recruiting
- Abiraterone Acetate
- +4 more
- Abiraterone acetate tablets
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Dec 30, 2021
Metastatic Castration-resistant Prostate Cancer Trial in China (TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- TQB3823 tablets
- +2 more
-
Chongqing, Chongqing, China
- +4 more
Jun 1, 2022
Prostate Cancer, Prostatic Tumor Trial in United States (abiraterone acetate in combination with prednisone)
Active, not recruiting
- Prostate Cancer
- Prostatic Neoplasm
- abiraterone acetate in combination with prednisone
-
Homewood, Alabama
- +44 more
Jan 17, 2023
Metastatic Castration-resistant Prostate Cancer Trial in United Kingdom, United States (PLX2853, Olaparib, Abiraterone acetate)
Terminated
- Metastatic Castration-resistant Prostate Cancer
- PLX2853
- +3 more
-
Chicago, Illinois
- +7 more
Oct 4, 2022